BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 8624164)

  • 1. High-dose methotrexate-induced bullous variant of acral erythema.
    Hellier I; Bessis D; Sotto A; Margueritte G; Guilhou JJ
    Arch Dermatol; 1996 May; 132(5):590-1. PubMed ID: 8624164
    [No Abstract]   [Full Text] [Related]  

  • 2. Bullous acral erythema secondary to high-dose methotrexate.
    Morrell DS; Challgren E; Eapen M; Esterly NB
    J Pediatr Hematol Oncol; 2002; 24(3):240. PubMed ID: 11990316
    [No Abstract]   [Full Text] [Related]  

  • 3. Methotrexate-induced bullous acral erythema in a child.
    Werchniak AE; Chaffee S; Dinulos JG
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S93-5. PubMed ID: 15858519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate-induced acral erythema with bullous reaction.
    Feizy V; Namazi MR; Barikbin B; Ehsani A
    Dermatol Online J; 2003 Feb; 9(1):14. PubMed ID: 12639472
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bullous variant of acral erythema in a child after high-dose methotrexate.
    Zils K; Wilhelm M; Reeh T; Bielack S
    Pediatr Hematol Oncol; 2012 May; 29(4):378-9. PubMed ID: 22568802
    [No Abstract]   [Full Text] [Related]  

  • 6. Acral erythema with oral methotrexate in a child.
    Varela CR; McNamara J; Antaya RJ
    Pediatr Dermatol; 2007; 24(5):541-6. PubMed ID: 17958806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outpatient high-dose methotrexate: proceed with extreme caution, if at all.
    Womer RB
    Pediatr Blood Cancer; 2010 Dec; 55(7):1250-1. PubMed ID: 20981687
    [No Abstract]   [Full Text] [Related]  

  • 8. Intravenous immunoglobulin in the treatment of severe methotrexate-induced acral erythema.
    Tezer H; Kuskonmaz B; Kara A; Devrim I; Tuncer M; Cengiz AB; Yetgin S; Seçmeer G
    J Pediatr Hematol Oncol; 2008 May; 30(5):391-3. PubMed ID: 18458576
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective.
    Mahadeo KM; Santizo R; Baker L; Curry JO; Gorlick R; Levy AS
    Pediatr Blood Cancer; 2010 Dec; 55(7):1296-9. PubMed ID: 20949591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A case of subacute transient cerebral dysfunction in a osteosarcoma patient following high-dose methotrexate].
    Yamada K; Takahashi M; Yoshida M
    Gan To Kagaku Ryoho; 2002 Mar; 29(3):469-72. PubMed ID: 11915742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bullous variant of acral erythema due to methotrexate.
    Kuruvila S; Dalal M; Sivanesan B
    Indian J Dermatol Venereol Leprol; 2006; 72(6):440-2. PubMed ID: 17179620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acral erythema caused by high-dose methotrexate therapy in patients with osteogenic sarcoma.
    Postovsky S; Ben Arush MW
    Pediatr Hematol Oncol; 2005 Mar; 22(2):167-73. PubMed ID: 15805003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acral erythema with bullous formation: a side effect of chemotherapy in a child with acute lymphoblastic leukemia.
    Aytaç S; Gümrük F; Cetin M; Tuncer M; Yetgin S
    Turk J Pediatr; 2010; 52(2):211-4. PubMed ID: 20560263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anaphylactoid reaction to high-dose methotrexate and successful desensitization.
    Oulego-Erroz I; Maneiro-Freire M; Bouzón-Alejandro M; Vázquez-Donsión M; Couselo JM
    Pediatr Blood Cancer; 2010 Sep; 55(3):557-9. PubMed ID: 20533520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed renal excretion of methotrexate after a severe anaphylactic reaction to methotrexate in a child with osteosarcoma.
    Ozguven AA; Uysal K; Gunes D; Koroglu T; Gurcu O; Olgun N
    J Pediatr Hematol Oncol; 2009 Apr; 31(4):289-91. PubMed ID: 19346884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose methotrexate is effective in osteosarcoma so what is the problem?
    Cohen IJ
    J Pediatr Hematol Oncol; 2009 Dec; 31(12):892-4. PubMed ID: 19887958
    [No Abstract]   [Full Text] [Related]  

  • 18. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma.
    Widemann BC; Balis FM; Kempf-Bielack B; Bielack S; Pratt CB; Ferrari S; Bacci G; Craft AW; Adamson PC
    Cancer; 2004 May; 100(10):2222-32. PubMed ID: 15139068
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bullous variant of chemotherapy-induced acral erythema.
    Waltzer JF; Flowers FP
    Arch Dermatol; 1993 Jan; 129(1):43-5. PubMed ID: 8420487
    [No Abstract]   [Full Text] [Related]  

  • 20. Acral erythema in children receiving high-dose methotrexate.
    Millot F; Auriol F; Brecheteau P; Guilhot F
    Pediatr Dermatol; 1999; 16(5):398-400. PubMed ID: 10571844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.